BofA raised the firm’s price target on Axon (AXON) to $750 from $525 and keeps a Buy rating on the shares. Building on the strong refresh cycle of TASER10 and incremental AI/Software product releases, the firm sees Axon’s top-line growth continuing at over 25% from 2024-26, the analyst tells investors. Axon being the only FedRAMP certified digital evidence vendor leaves the company well positioned to the incoming administration’s priorities, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXON:
- Cantor sees six changes to Nasdaq 100 Index in December rebalance
- Axon awarded Federal Government contract to supply RCMP with cameras
- AXON Stock: Remarkable Growth, but the Valuation Poses Risk
- Axon price target raised to $585 from $387 at Barclays
- Axon price target raised to $610 from $500 at JMP Securities